Top Suppliers:I want be here

  • DC Chemicals Limited
  • China
  • Product Name: AMG-511
  • Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/1g
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao

1253573-53-3

1253573-53-3 structure
1253573-53-3 structure
  • Name: AMG 511
  • Chemical Name: 1,​3,​5-​Triazin-​2-​amine, 4-​[2-​[(5-​fluoro-​6-​methoxy-​3-​pyridinyl)​amino]​-​5-​[(1R)​-​1-​[4-​(methylsulfonyl)​-​1-​piperazinyl]​ethyl]​-​3-​pyridinyl]​-​6-​methyl
  • CAS Number: 1253573-53-3
  • Molecular Formula: C22H28FN9O3S
  • Molecular Weight: 517.58000
  • Catalog: Signaling Pathways PI3K/Akt/mTOR PI3K
  • Create Date: 2016-07-11 08:34:06
  • Modify Date: 2024-01-19 18:09:56
  • AMG 511 is a potent and orally available pan inhibitor of class I PI3Ks, with Kis of 4 nM, 6 nM, 2 nM and 1 nM for PI3Kα, β, δ and γ, respectively. AMG 511 significantly suppresses PI3K signaling that is indicated by p-Akt (Ser473) decrease. AMG 511 exhibits anti-tumor activity in mouse glioblastoma xenograft model[1].

Name 1,​3,​5-​Triazin-​2-​amine, 4-​[2-​[(5-​fluoro-​6-​methoxy-​3-​pyridinyl)​amino]​-​5-​[(1R)​-​1-​[4-​(methylsulfonyl)​-​1-​piperazinyl]​ethyl]​-​3-​pyridinyl]​-​6-​methyl
Synonyms amg-511
Description AMG 511 is a potent and orally available pan inhibitor of class I PI3Ks, with Kis of 4 nM, 6 nM, 2 nM and 1 nM for PI3Kα, β, δ and γ, respectively. AMG 511 significantly suppresses PI3K signaling that is indicated by p-Akt (Ser473) decrease. AMG 511 exhibits anti-tumor activity in mouse glioblastoma xenograft model[1].
Related Catalog
Target

PI3Kα:4 nM (Ki)

PI3Kβ:6 nM (Ki)

PI3Kδ:2 nM (Ki)

PI3Kγ:1 nM (Ki)

In Vitro AMG 511 shows the inhibition of AKT (Ser473) phosphorylation in U87 malignant glioma (MG) cells with an IC50 of 4 nM[1].
In Vivo AMG 511 potently blocks the targeted PI3K pathway in a mouse liver pharmacodynamic model (3-30 mg/kg; p.o.) and inhibits tumor growth in a U87 MG glioblastoma xenograft model (3-30 mg/kg; p.o.; daily; for 12 days)[1]. AMG 511 shows excellent in vivo efficacy and pharmacokinetic profile[1]. Animal Model: Female CD1 NU/NU mice, with U87 MG glioblastoma xenograft model[1] Dosage: 1 mg/kg, 3 mg/kg, 10 mg/kg Administration: Oral administration, daily, for 12 days Result: Inhibited tumor growth. Animal Model: Male Sprague-Dawley rats[1] Dosage: 1 mg/kg Administration: Oral administration (Pharmacokinetic Analysis) Result: Had a superior pharmacokinetic profile with low clearance (0.4 L/h/kg, 12% of liver blood flow), good oral bioavailability (F = 60%), and a commensurate high oral exposure (AUC = 5.0 μM·h).
References

[1]. Mark H Norman, et al. Selective Class I Phosphoinositide 3-kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511. J Med Chem. 2012 Sep 13;55(17):7796-816.

Molecular Formula C22H28FN9O3S
Molecular Weight 517.58000
Exact Mass 517.20200
PSA 160.73000
LogP 3.35950
Hazard Codes Xn